Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Monash IVF Group Ltd ( (AU:MVF) ) has shared an update.
Monash IVF Group Limited, a leading Australian fertility services and IVF provider, operates in the healthcare sector with a focus on assisted reproductive technologies and related treatments for patients seeking fertility solutions. The company recently appointed Dr Victoria Atkinson as CEO, with the Board backing her strategy to restore stability and drive growth following a period of instability.
Monash IVF has rejected a revised, unsolicited, conditional and non-binding takeover proposal from a Genesis Capital and Soul Patts consortium offering $0.90 per share, judging that it undervalues the company and is not in shareholders’ best interests. The Board cited the discount to comparable IVF transactions, renewed leadership under Dr Atkinson, and feedback from non-consortium investors, while signalling it remains open to higher-value change-of-control offers and will continue to assess any proposals in line with shareholder value.
The most recent analyst rating on (AU:MVF) stock is a Buy with a A$0.90 price target. To see the full list of analyst forecasts on Monash IVF Group Ltd stock, see the AU:MVF Stock Forecast page.
More about Monash IVF Group Ltd
Monash IVF Group Limited is an Australian fertility services provider specialising in in-vitro fertilisation and related reproductive health treatments. The company operates in the healthcare sector, focusing on assisted reproductive technologies and fertility solutions for patients across Australia and potentially selected international markets.
Average Trading Volume: 810,681
Technical Sentiment Signal: Sell
Current Market Cap: A$296.1M
See more insights into MVF stock on TipRanks’ Stock Analysis page.